T cell response not critical for immune memory to SARS-CoV-2 or recovery from COVID-19
Research News Release
EurekAlert! provides eligible reporters with free access to embargoed and breaking news releases.
Eligibility GuidelinesEurekAlert! offers eligible public information officers paid access to a reliable news release distribution service.
Eligibility GuidelinesEurekAlert! is a service of the American Association for the Advancement of Science.
New research conducted in monkeys reveals that T cells are not critical for the recovery of primates from acute COVID-19 infections.
How early is the course of COVID-19, mild or severe, determined? In Cell, researchers examined nasal cells sampled from patients at the time of diagnosis, looking for differences between those who developed severe disease and those who experienced a mild illness. Cells from patients who developed severe COVID-19 exhibited a more muted antiviral response. If the early stages of infection can determine disease severity, it opens a path for scientists to develop early therapeutic interventions.
There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science.
As reported in the journal Science, Leor Weinberger and his team at Gladstone Institutes have discovered a pathway they named discordant transcription through repair (DiThR, pronounced "dither"). The DiThR pathway appears to boost the noisiness of gene expression in stem cells and enhance their ability to differentiate.
Researchers at Cornell have developed a way to analyze how individual immune cells react to the bacteria that cause tuberculosis. It could pave the way for new vaccine strategies and provide insights into fighting other infectious diseases.
Replication of SARS-CoV-2, the virus responsible for COVID-19, depends on a series of interactions between viral proteins and different cellular partners such as nucleic acids (DNA or RNA). Characterizing these interactions is crucial to elucidate the process of viral replication and identify new drugs for treating COVID-19.
Alexandria, Va., USA - Iain Chapple, University of Birmingham, England, presented the oral session "Longitudinal Serological and Vaccination Responses to SARS-COV-2 in Dental Professionals" at the virtual 99th General Session & Exhibition of the International Association for Dental Research (IADR), held in conjunction with the 50th Annual Meeting of the American Association for Dental Research (AADR) and the 45th Annual Meeting of the Canadian Association for Dental Research (CADR), on July 21-24, 2021.
Scientists have developed a 'nanobody' - a small fragment of a llama antibody - that is capable of chasing out human cytomegalovirus (HCMV) as it hides away from the immune system. This then enables immune cells to seek out and destroy this potentially deadly virus.
A computational analysis of COVID-19 tests suggests that, in order to minimize the number of infections in a population, the amount of testing matters more than the sensitivity of the tests that are used. Philip Cherian and Gautam Menon of Ashoka University in Sonipat, India, and Sandeep Krishna of the National Centre for Biological Sciences TIFR, Bangalore, India, present their findings in the open-access journal PLOS Computational Biology.
A computational analysis of COVID-19 tests suggests that, in order to minimize the number of infections in a population, the amount of testing matters more than the sensitivity of the tests that are used. Philip Cherian and Gautam Menon of Ashoka University in Sonipat, India, and Sandeep Krishna of the National Centre for Biological Sciences TIFR, Bangalore, India, present their findings in the open-access journal PLOS Computational Biology.